Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.00 – $0.50
0% from low
Exchange
OTC Link
CS
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $2.5M | $3.5M | $3.1M | $0 | $0 | $0 | $0 |
| Cost of revenue | $416.0K | $782.7K | $3.2M | $4.0M | $47.4K | $70.5K | $61.7K | $624 |
| Gross profit | −$416.0K | $1.7M | $208.5K | −$126.0K | −$47.4K | −$70.5K | −$61.7K | −$624 |
| Gross margin | — | 68.8% | 6.0% | -4.0% | — | — | — | — |
| R&D | $0 | $0 | $458.8K | $0 | $352 | $821.3K | $490.3K | $261.6K |
| Operating income | −$8.9M | −$17.8M | −$13.2M | −$12.0M | −$2.0M | −$1.9M | −$1.7M | −$1.4M |
| EBITDA | −$8.5M | −$17.2M | −$16.3M | −$9.8M | −$2.0M | −$1.8M | −$1.6M | −$1.4M |
| Net income | −$9.9M | −$23.0M | −$23.7M | −$12.4M | −$3.7M | −$531.0K | −$4.1M | −$1.4M |
| Net margin | — | -915.3% | -684.6% | -396.5% | — | — | — | — |
| EPS (diluted) | -0.13 | -0.17 | -0.11 | -0.04 | -0.01 | -0.00 | -0.01 | -0.00 |
Annual figures · source: Financial Modeling Prep
GB SCIENCES INC
No one on the platform currently holds GBLX.
No tracked institution reports a position in GBLX as of their last filing.
No one on the platform has traded GBLX yet.
| $124111 |
| — |
| HTDSHard to Treat Diseases Inc. | $0.00 | +0.00% | $109647 | — |
| IRBSIR Biosciences Holdings Inc. | $0.00 | +0.00% | $128122 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Fundamental analysis of $GBLX (GB SCIENCES INC) based on financial data and reported results. #GBLX
View on StockTwits ↗$GBLX I ve been trying to buy this hot garbage pile for a month and ive only filled 30 shares.
View on StockTwits ↗$GBLX we all got screwed with this scam stock
View on StockTwits ↗$GBLX Market Cap 1.3M is laughable. This company used to have promise until it decided to go the route of being a biopharmaceutical yet 5-7 years later and they are sub penny. How they remain listed and their LinkedIn is locked down from posting. This company is one big scam. Anyone who dared to invest all their money went straight to the pockets of crappy management and a so called doctor.
View on StockTwits ↗Merck and Murderna $MRK $MRNA are trying to convince investing public in using GMO lipids that cause cancer can cure cancer Keytruda comes off of patent in 2028 GB Sciences $GBLX has natural cannabis based lipids that can be used with Keytruda Fenbendazole and Ivermectin for cancer and Alzheimers Dementia Parkinsons MS etc.
View on StockTwits ↗@axelvento999 with that avatar you should have been buying $GBLX Maybe that's who MRK will buy
View on StockTwits ↗$BNTX $PFE so why do you think the natural lipid maker $GBLX has doubled in value?
View on StockTwits ↗$MRNA meanwhile the natural lipid maker has doubled in value over the last week $GBLX Because GMO lipids have never been needed
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.